Kentaro Hayashida
Latest contributions
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
PCR Tokyo Valves 2026 Closing Ceremony
15 Feb 2026 – From PCR Tokyo Valves 2026
The Closing Ceremony marks the conclusion of this cardiology conference, providing a formal wrap-up and reflection on the key highlights and advancements presented throughout the event. It serves as an opportunity to acknowledge contributors and set the stage for future initiatives in interventional cardiology.
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
PCR Tokyo Valves 2026 Welcome Ceremony
14 Feb 2026 – From PCR Tokyo Valves 2026
The Welcome Ceremony marks the commencement of the conference, setting the stage for an engaging and informative program dedicated to advances in cardiology and interventional techniques. It provides attendees with an overview of the event's objectives and highlights the collaborative spirit of the cardiology community.
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Design that delivers the future of TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
This session presents the future of TAVI valve design, emphasizing supra-annular valve benefits, strategies for managing concomitant coronary artery disease, and redo-TAVI approaches tailored for long-term patient management.
Mastering techniques from basic to complex - TAVI basics
13 Feb 2026 – From PCR Tokyo Valves 2026
This session offers a comprehensive overview of Transcatheter Aortic Valve Implantation (TAVI) fundamentals, focusing on CT scan analysis for optimal patient and valve selection, strategies to avoid procedural complications, and approaches to streamline TAVI procedures for improved outcomes.
TAV in TAVI with coronary protection - LIVE Case
18 Nov 2025 – From PCR London Valves 2025
Watch a LIVE case followed by a recorded case, regarding a 78-year-old female, with a previous TAVI in 2014 (Sapien 3 26) and sarcoidosis, who presented with symptomatic TAVI stenosis. There was a mis-commissural alignment, with the neoskirt plane above the coronary plane. Under general anesthesia,...
TAVI in 2025: transforming care with the new valvular heart disease guidelines
18 Nov 2025 – From PCR London Valves 2025
This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient...
TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture
17 Nov 2025 – From PCR London Valves 2025
This session presents critical case analyses of complicated TAVI procedures, highlighting unexpected and severe intra-procedural events such as annular perforation, leaflet modification complications, coronary obstructions, and device failures. It emphasizes prevention strategies, bailout techniques, and acute management to prepare clinicians for handling TAVI-related emergencies effectively.
How to optimise TAVI outcomes in extreme patient anatomies?
16 Nov 2025 – From PCR London Valves 2025
Explore strategies to optimise TAVI outcomes in patients with extreme anatomies in this PCR London Valves 2025 session.
Through case-based discussions, the session addresses challenges in small annular anatomy, approaches for large annuli, and strategies to ensure optimal lifetime management for younger TAVI patients. Learn practical tips...
Tricuspid, mitral and structural innovations
11 Oct 2025 – From AICT-AsiaPCR 2025
This session presents a comprehensive overview of innovative interventions addressing complex structural heart conditions, including tricuspid and mitral valve diseases. Highlights include clinical experiences from the PESCAMI registry on mitral indirect annuloplasty, advanced percutaneous procedures for large pulmonary arteriovenous malformations, and transcatheter bicaval valve implantation for...
Valve-in-valve in degenerated surgical bioprothesis mitral valve - LIVE Case
10 Oct 2025 – From AICT-AsiaPCR 2025
A 78-year-old male with a history of rheumatic disease underwent surgical mitral valve replacement (Perimount Magna 25), surgical aortic valve replacement (Perimount Magna), and CABG (LIMA–LAD) in 2010. He presented with symptomatic severe mitral regurgitation and normal LV function.
He was treated with implantation of a 26...
Best Clinical Cases of AICT-AsiaPCR 2025
10 Oct 2025 – From AICT-AsiaPCR 2025
This session showcases the best clinical cases from AICT-AsiaPCR 2025, highlighting complex scenarios such as post-trauma ST-elevations, transcatheter aortic valve implantation complexities, CTO-PCI in high-bleeding-risk patients, and challenging device retrievals. It emphasizes clinical decision-making and innovative interventional techniques in diverse cardiac pathologies.
How to optimise TAVI outcomes in the Asian-Pacific population?
22 May 2025 – From EuroPCR 2025
What are the key considerations for TAVI in Asian-Pacific patients? This EuroPCR 2025 session focuses on optimising outcomes in anatomically and clinically specific contexts, such as patients with small annuli. Learn how the latest intra-annular self-expanding devices can help reduce post-procedural pacemaker implantation (PPI) rates, and...
TAVI in bicuspid: all you need to know
22 May 2025 – From EuroPCR 2025
Understand the unique anatomical and clinical challenges of transcatheter aortic valve implantation (TAVI) in bicuspid aortic valves. This session covers bicuspid valve epidemiology, indications for surgery and TAVI, and detailed discussion on sizing and deployment fundamentals specific to bicuspid anatomy to optimize procedural success.
TAV-in-TAV in SAV 3 valves procedures
21 May 2025 – From EuroPCR 2025
Examine the complexities of TAV-in-TAV procedures in degenerated surgical aortic valves (SAV) and TAVI valves. This session discusses cases involving massive aortic regurgitation, lifetime management challenges, and valve-in-valve-in-valve scenarios, providing practical insights into managing multiple valve interventions and associated complications.
Complex PCI in a TAVI patient - LIVE case
20 May 2025 – From EuroPCR 2025
An 84-year-old patient with a history of ischemic stroke in 2017, hypertension, diabetes, dyslipidemia, and a preserved LV function (63 %) presented with a severe symptomatic aortic stenosis. The coronary angiography revealed a severe and calcified stenosis of the distal left main.
Operators implanted an Edwards Sapien...
How to manage the challenges of TAVI in bicuspid disease?
22 May 2025 – From EuroPCR 2025
How should TAVI be adapted to the unique challenges of bicuspid aortic valve disease? In this EuroPCR 2025 discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche explore the key anatomical and procedural considerations for tailoring treatment. From selecting which bicuspid anatomies are suitable for TAVI...
Valve in valve in small degenerative surgical bioprosthesis - LIVE case
09 Feb 2025 – From PCR Tokyo Valves 2025
A 74-year-old female with a permanent pacemaker and preserved LV function presented with a symptomatic degenerative surgical valve (SJ Epic 21) implanted in 2016.
Patient underwent implantation of an Evolut FX 26 mm under general anesthesia with cerebral embolic protection and TEE guidance. A surgical valve fracture...
PCR Tokyo Valves 2025 Closing Ceremony
09 Feb 2025 – From PCR Tokyo Valves 2025
Join us for the powerful closing ceremony of PCR Tokyo Valves 2025, following a course that gathered 1,200 participants. Watch the winner of the best clinical case present his complex case of severe aortic stenosis, left main coronary artery dissection, and severe primary mitral regurgitation in...
More possibilities in TEER - Treatment of degenerative mitral regurgitation
09 Feb 2025 – From PCR Tokyo Valves 2025
Through case reviews, explore the latest advancements in transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation. Discover how a novel TEER device expands treatment possibilities, offering predictable and durable results.
Transcatheter management of failed THV - LIVE case
Recommended by PCR
09 Feb 2025 – From PCR Tokyo Valves 2025
An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...
TAVI in small annulus - LIVE case
08 Feb 2025 – From PCR Tokyo Valves 2025
A 79-year-old female with CAD (stenosis in the mid-LAD), asthma, and diabetes presented with symptomatic severe aortic stenosis. Left ventricular function was preserved, with an annulus measuring 355 mm², and the valves were heavily calcified.
A Navitor Vision valve was implanted with predilatation (18 mm balloon) under...
The value of WATCHMAN therapy - Who should we treat?
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the value of WATCHMAN therapy in this sponsored session by Boston Scientific. Explore the latest evidence and future perspectives of this innovative treatment option. Understand who the ideal patient is for WATCHMAN therapy and how to identify them in daily clinical practice, including TAVI...
